Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Viking Therapeutics (VKTX) Tops Q1 EPS by 2c
May 2, 2019 4:13 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).
"The progress and momentum we achieved during 2018 have continued into 2019," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "At the recent EASL conference, we... More
